MedTrace Logo

Advanced Refractory Solid Tumors With TP53 Mutations Register Study

NCT03927599 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-08-20

No results posted yet for this study

Summary

The efficacy and safety of the PARP inhibitor in combination with the VEGFR inhibitor will be investigated in advanced refractory solid tumors patients with TP53 mutation .

Conditions

  • Solid Tumor, Adult

Interventions

OTHER

Data Collection

Colleciton of data from medical records only

Sponsors & Collaborators

  • Tianjin Medical University Second Hospital

    lead OTHER

Principal Investigators

  • Haitao Wang · Tianjin Medical Unversity Second Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-12-31
Completion
2020-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927599 on ClinicalTrials.gov